The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - A phase IV randomised clinical trial with ranibizumab: The FLUID study

BMC Ophthalmology

Volumn 16, Issue 1, 2016, Pages

  Arnold, Jennifer J ^a   Markey, Caroline M ^b   Kurstjens, Nicol P ^c   Guymer, Robyn H ^d  

^a Marsden Eye Specialists   (Australia)

^b Markey Medical Consulting Pty Ltd   (Australia)

^c Pty Ltd   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Intra retinal fluid; Neovascular AMD; Ranibizumab; Sub retinal fluid; Treat and extend regimen

Indexed keywords

ANGIOGENESIS INHIBITOR; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 4 CLINICAL TRIAL; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBRETINAL FLUID; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84962408693     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/s12886-016-0207-3     Document Type: Article

References (26)

1. Deloitte Access Economics. Eyes on the future: A clear outlook on age-related macular degeneration. Macular Degeneration Foundation. 2011. Available at www.mdfoundation.com.au/LatestNews/MDFoundationDeloitteAccessEconomicsReport2011.pdf. Accessed 15 March 2016.
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31.
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study. Ophthalmology. 2009;116:57-65.
4. Novartis Pharmaceuticals Australia. Lucentis Australian Prescribing Information. 2011.
5. Eldem MB, Bartz-Schmidt KU, Schlingemann RO, Guymer R, Axer-Siegel R, on behalf of the EXCITE study group. Visual acuity response profiles in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial. Invest Ophthalmol Vis Sci. 2009;50:2374.
6. Frampton JE. Ranibizumab: A review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging. 2013;30:331-58.
7. Holz FG, Korobelnik JF, Laznetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, et al. The effects of a flexible visual acuity-driven regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. 2010;51:405-12.
8. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663-71.
9. Kovach JL, Schwartz SG, Flynn Jr HW, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthamol. 2012;2012:786870.
10. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58.
11. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908.
12. CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE. Ranibizumab and bevacizumab for treatment of neovascular age-related Macular degeneration. Two-year results. Ophthalmology. 2012;119:1388-98.
13. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. the HARBOR study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046-56.
14. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2010;117:2134-40.
15. Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, et al. Inject and extend dosing versus dosing as needed. A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31:26-30.
16. Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina. 2013;33:1351-8.
17. Abedi F, Wickremasinghe S, Islam AFM, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration. A treat-and-extend protocol over 2 years. Retina. 2014;34:1531-8.
18. Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye. 2015;29:450-1.
19. Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology. 2014;121:676-81.
20. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, et al. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212-1219.
21. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679-80.
22. Schmidt-Erfurth U, Kaiser P, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology. 2014;121:193-201.
23. Grunwald JE, Daniel E, Huang J, Ying GS, Maquire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatment trials. Ophthalmology. 2014;121:150-61.
24. Brantley Jr MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168-73.
25. Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PM. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology. 2013;120:1641-8.
26. National Institute of Health Clinical Trials Registration Number.